TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03831893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nopal food product 1
Description: Dried Nopal incorporated in a food product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nopal food product 2
Description: Dried Nopal incorporated in a food product

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: Food Product without nopal
Study: NCT03867461

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment to Mean Arterial Pressure (60-80 mmHg range)
Description: Mean arterial pressure will be adjusted to fall in the 60-80 mmHg range

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)
Description: End-tidal carbon dioxide concentrations will be adjusted to fall in the 24-26 mmHg range
Study: NCT04407091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C]AZD4831 Oral Solution
Description: 10 mg dose of \[14C\]AZD4831 Oral Solution
Study: NCT01175213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)
Description: Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)
Description: Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IV treatment with IGSC, 10%
Description: During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
Study: NCT04129086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine plus usual care
Description: Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
Study: NCT00702923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide and CP-675,206 (Tremelimumab)
Description: Dose level -1 :~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)
Study: NCT04129086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
Study: NCT03655587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solid ankle foot orthotic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resting night splint
Study: NCT03324932

Intervention type: DRUG
Group type: OTHER
Intervention: Denosumab Injection
Description: AI intake + denosumab injection per 6 months VS only AI intake
Study: NCT01003093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 microgram antigen (Ag85B + ESAT-6)
Description: 0.5 mL suspension for injection x 2 with 2 months interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a
Description: 0.5 mL suspension for injection x 2 with 2 months interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a
Description: 0.5 mL suspension for injection x 2 with 2 months interval
Study: NCT01753947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deliberate Practice
Study: NCT03948126

Intervention type: OTHER
Intervention: Questionnaire about geophagia (knowledge about soil/clay consumption and knowledge of the health effects of geophagy)
Study: NCT02810951

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FCX-007
Description: FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.
Study: NCT01410799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone Releasing Hormone (GHRH )
Description: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
Study: NCT00702923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide, CP-675,206 (tremelimumab)
Description: Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide, CP-675,206 (Tremelimumab)
Description: Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide, CP-675,206 (Tremelimumab)
Description: Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide, CP-675,206
Description: Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29
Study: NCT01275040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile screening; Health Education
Description: Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
Study: NCT00785265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-Based (GB) Intervention
Description: 60-minute group session involving other study patients who have been assigned to this condition and their guests.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based (HB) Intervention
Description: 60-minute educational intervention in their home, which will be delivered by an African American health educator.
Study: NCT01847378

Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
Study: NCT02217878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: IV bolus injection
Study: NCT01787799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY
Description: Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.
Study: NCT02217878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV bolus injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 180 mg loading dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor
Description: 180 mg loading dose
Study: NCT02771431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-rounding in post operative care
Description: Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
Study: NCT00992602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine
Description: Given IT or via LP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03769883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and diet
Description: The participants will undergo diet or combined diet and exercise. The exercise will be provided at different volumes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and diet
Description: The participants will undergo diet or combined diet and exercise. The exercise will be provided at different volumes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Dietary intervention
Study: NCT01916590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine
Description: After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00532714

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Irinotecan plus capecitabine
Description: Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period).
Study: NCT03780491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cost Discussion
Description: The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
Study: NCT02475850

Intervention type: OTHER
Group type: OTHER
Intervention: Evidence-based tailored fall prevention

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study: NCT01019772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBVH0101 (Hib vaccine)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™ Vaccine
Study: NCT01772836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biapenem
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biapenem
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biapenem
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
Study: NCT04863937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal Thigh Compression Garment, Knee Sleeve
Description: Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
Study: NCT00835003

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective caesarean section
Description: Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective caesarean section
Description: Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
Study: NCT04183894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Intervention
Description: Participants will receive a personalized intervention based on their personalized network.
Study: NCT04843826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: papilla reconstruction
Description: subepithelial connective tissue graft for interdental papillary reconstruction around delayed
Study: NCT01125618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health and development intervention package
Description: The timing and sequence of intervention vary by site, but include improved access to seed-fertilizer to increase agricultural production; improved market and capital access; proven maternal-newborn-child health interventions delivered free of cost at the point of service; improvements to school number and quality; and access to basic infrastructure including safe water, sanitation, electricity, transport and communication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine services
Description: Routine services and programs currently being administered using prevailing resources, at the current pace and with established partnerships. There is no attempt to limit the introduction of new interventions or agencies into comparison sites.
Study: NCT04715412

Intervention type: OTHER
Group type: OTHER
Intervention: patient counseling and adherence support
Description: Technical interventions include; identification of possible reasons for non-adherence, adherence support by developing simplified schedules for taking medications that were customized to individualized patient's lifestyle. Reminders for dose as well as tools/strategies the RTR may use to follow the dosing schedules if needed as pillbox were provided as needed~Clinical pharmacists' guided patient training was individualized, repetitive, covered 6 months, and included more aspects and provided practical hints and strategies for medication management.~Initial clinical pharmacist face-to-face session will be up to 60-minute then 30-minute follow-up sessions will be conducted monthly for 6 months during the scheduled post-transplant clinic visits as coordinated with the transplant physician to allow for single office visits for transplant related issues and comorbidities.
Study: NCT03943888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection 2mg/kg
Description: Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection 4mg/kg
Description: Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection 8mg/kg
Description: Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular reversal agent injection
Description: Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
Study: NCT02205398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Study: NCT03919838

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: A half of the participants will be randomly allocated to the probiotics group. They will receive two probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - No probiotics
Description: A half of the participants will be randomly allocated to the placebo group. They will receive two no probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
Study: NCT02576015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-operative continuous femoral nerve block with light sedation
Description: this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: post-operative continuous femoral nerve block
Description: this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulated needle (Contiplex B Braun, Melsungen, Germany)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline
Study: NCT04327518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECNIS® Toric II
Description: Toric Intraocular Lens
Study: NCT01823770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine
Description: Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
Study: NCT00792090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented milk
Description: Formula used for non breastfed children or in complement of breastfeeding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard milk
Description: Formula used for non breastfed children or in complement of breastfeeding
Study: NCT01823770

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patchs
Description: Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
Study: NCT02133742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib at starting dose of 5 mg and 3 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
Study: NCT02148211

Intervention type: OTHER
Intervention: Data collection
Description: Initial and follow-up data was collected using questionnaires.
Study: NCT04261049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide Extended-Release Injectable Suspension
Description: A single ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) intra-articular knee injection.
Study: NCT00860418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pediatric Asthma Alert (PAAL)
Description: Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard asthma education
Description: Standard asthma education during 2 home visits.
Study: NCT02027415

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet juice
Description: 2 cups of beet juice will be given before the car ride

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet juice
Description: 2 cups of beet juice will be given before the car ride